SSP+ 3.05 G — DIN 02492067
DISODIUM PHOSPHATE : 3.05 G MAGNESIUM CHLORIDE : 0.3 G SODIUM CITRATE : 3.18 G SODIUM ACETATE : 4.42 G SODIUM CHLORIDE : 4.05 G POTASSIUM CHLORIDE : 0.37 G SODIUM PHOSPHATE MONOBASIC : 1.05 G · MACO PHARMA · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is SSP+?
SSP+ 3.05 G contains DISODIUM PHOSPHATE : 3.05 G MAGNESIUM CHLORIDE : 0.3 G SODIUM CITRATE : 3.18 G SODIUM ACETATE : 4.42 G SODIUM CHLORIDE : 4.05 G POTASSIUM CHLORIDE : 0.37 G SODIUM PHOSPHATE MONOBASIC : 1.05 G. It is listed in the Health Canada Drug Product Database under DIN 02492067, held by MACO PHARMA, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 05-Nov-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is SSP+ used for?
SSP+ (platelet additive solution E) is an isotonic solution designed to partially replace plasma in the preparation and storage of buffy-coat derived platelet concentrates or apheresis platelet units and enable platelets to be stored in a mix of SSP+ and plasma at 20°C - 24°C, under gentle agitation, for up to 7 days following collection and according to local regulations.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Blood Transfusion, Auxiliary Products in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
11 holders have a Canadian DIN containing Blood Transfusion, Auxiliary Products, across 25 DINs, of which 12 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| BAXTER CORPORATION | 6 | 4 | 1.6% SODIUM CHLORDIE PROCESSING SOLUTION, 12% SODIUM CHLORDIE PROCESSING SOLUTION, ANTICOAGULANT CIT PHOS DEX ADENINE SOL USP, ANTICOAGULANT SOD CITRATE SOLTN 4GM/100ML, ANTICOAGULANT SODIUM CITRATE 4% W/V SOLUTION, USP, +1 more | Sourceable in Canada |
| MACO PHARMA | 4 | 4 | ADDITIVE SOLUTION SODIUM ADENINE GLUCOSE MANNITOL (SAGM), ANTICOAGULANT SOLUTION CITRATE PHOSPHATE DEXTROSE (CPD), SSP+ | Sourceable in Canada |
| FRESENIUS KABI AG | 3 | 2 | ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) FORMULA A, GLYCEROLYTE 57 SOLUTION | Sourceable in Canada |
| TERUMO BCT, INC. | 2 | 1 | ADDITIVE SOLUTION FORMULA 3 AS-3, ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) FORMULA A | Sourceable in Canada |
| FRESENIUS KABI CANADA LTD | 1 | 1 | ANTICOAGULANT SODIUM CITRATE SOLUTION, USP | Sourceable in Canada |
| CUTTER MED & BIOL, DIVISION OF MILES CANADA LTD. | 2 | 0 | ANTICOAGULANT CITRATE DEXTR SOL FORMULA A USP, ANTICOAGULANT SODIUM CITRATE SOL 4% USP | No marketed DIN |
| FENWAL INC | 2 | 0 | ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) FORMULA B, ANTICOAGULANT SODIUM CITRATE SOLUTION USP | No marketed DIN |
| FENWAL LABS, DIVISION OF BAXTER CORPORATION | 2 | 0 | BLOOD PACK UNIT CPD, CPD ADENINE CPDA 1 | No marketed DIN |
| DRAXIMAGE A DIVISION OF DRAXIS SPECIALTY PHARMACEUTICALS INC | 1 | 0 | A-C-D SOLUTION | No marketed DIN |
| HAEMONETICS CORPORATION | 1 | 0 | SAG-M | No marketed DIN |
| HOSPIRA HEALTHCARE ULC | 1 | 0 | HEPARIN LOCK FLUSH SOLUTION INJ 10UNIT/ML | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 3.05 G |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | Buffy coat production method: 250 mL, 280 mL, 300 mL; Apheresis method: 280 mL, 300 mL, 500 mL |
| Storage | Store SSP+ (platelet additive solution E) at a temperature between 15°C and 30°C. Platelets in SSP+ solution can be stored between 20°C and 24°C for up to 7 days under gentle agitation following collection. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Blood Transfusion, Auxiliary Products |
|---|---|
| ATC code | V07AC |
| AHFS class | 96:00.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02492067 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2492067 |
| Brand name | SSP+ |
| Generic / active ingredient | DISODIUM PHOSPHATE : 3.05 G MAGNESIUM CHLORIDE : 0.3 G SODIUM CITRATE : 3.18 G SODIUM ACETATE : 4.42 G SODIUM CHLORIDE : 4.05 G POTASSIUM CHLORIDE : 0.37 G SODIUM PHOSPHATE MONOBASIC : 1.05 G |
| Market authorization holder | MACO PHARMA |
| Health Canada schedule | Ethical |
| ATC code | V07AC |
| ATC anatomical main group | V — Various |
| ATC therapeutic subgroup | V07AC |
| Current status | MARKETED |
| Status date | 05-Nov-2021 |
| Original market date | 2021-11-05 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
12 of 25 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| 12% SODIUM CHLORDIE PROCESSING SOLUTION | 12 G / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | 00783625 |
| ADDITIVE SOLUTION SODIUM ADENINE GLUCOSE MANNITOL (SAGM) | 8.77 G | SOLUTION | MACO PHARMA | MARKETED | 02444097 |
| ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) FORMULA A | 2.45 G / 100 ML | SOLUTION | FRESENIUS KABI AG | MARKETED | 00788139 |
| ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) FORMULA A | 2.45 G / 100 ML | SOLUTION | TERUMO BCT, INC. | MARKETED | 02469731 |
| ANTICOAGULANT SOD CITRATE SOLTN 4GM/100ML | 4 G / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | 00060313 |
| ANTICOAGULANT SODIUM CITRATE 4% W/V SOLUTION, USP | 4 G / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | 02377411 |
| ANTICOAGULANT SODIUM CITRATE SOLUTION, USP | 4 G / 100 ML | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | 02529637 |
| ANTICOAGULANT SOLUTION CITRATE PHOSPHATE DEXTROSE (CPD) | 25.5 G | SOLUTION | MACO PHARMA | MARKETED | 02444100 |
| DEXTROSE 0.2% AND 0.9% SOD CHLOR SOLUTION | 900 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | 00783641 |
| GLYCEROLYTE 57 SOLUTION | 30 MG / 100 ML | SOLUTION | FRESENIUS KABI AG | MARKETED | 00783668 |
2 · Same class — other molecules in ATC V07AC
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Blood Transfusion, Auxiliary Products | 1.6% SODIUM CHLORDIE PROCESSING SOLUTION · 12% SODIUM CHLORDIE PROCESSING SOLUTION · A-C-D SOLUTION · ADDITIVE SOLUTION FORMULA 3 AS-3 · +18 more | 25 | 12 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC V07A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| V07AB | Solvents And Diluting Agents, Incl Irrigat Solut | 62 | 23 |
| V07AV | Technical Disinfectants | 6 | 1 |
| V07AD | Blood Tests, Auxiliary Products | 2 | 0 |
| V07AT | Cosmetics | 1 | 0 |
| V07AX | Washing Agents Etc. | 3 | 0 |
| V07AY | Other Non-Therapeutic Auxiliary Products | 6 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.